Abstract
BackgroundImmune checkpoint blockade (ICB) has revolutionized our approach to cancer treatment. However, the response rate of immune checkpoint blockade (ICB) is still low. With the accumulation of large-scale ICB data,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
